Profile
Benjamin Kelmendi is the founder of Transcend Therapeutics, Inc. (New York) and held the title of Chief Scientific Advisor.
Benjamin Kelmendi active positions
Companies | Position | Start |
---|---|---|
Transcend Therapeutics
Transcend Therapeutics BiotechnologyHealth Technology Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Transcend Therapeutics
Transcend Therapeutics BiotechnologyHealth Technology Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access. | Health Technology |
- Stock Market
- Insiders
- Benjamin Kelmendi